Diamyd Medical accelerates Phase 3 Type 1 diabetes trial following FDA guidance
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Subscribe To Our Newsletter & Stay Updated